A phase II study of ganetespib (G) as second- or third-line therapy for metastatic pancreatic cancer (MPC).

被引：1
|
作者：
Thota, Ramya
Goff, Laura Williams
Chan, Emily
Berlin, Jordan
Jones, C. Michael
McClanahan, Pamela
Ayers, Gregory Dan
Cardin, Dana Backlund
机构：
[1] Vanderbilt Univ, Nashville, TN 37235 USA
[2] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[3] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[4] Jones Clin, Germantown, TN USA
[5] Vanderbilt Univ, Div Canc Biostat, Nashville, TN 37235 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.297
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
297
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II study of recombinant IL-21 (rIL-21) plus sorafenib as second- or third-line therapy for metastatic renal cell cancer (mRCC): Final results
    Bhatia, S.
    Heath, E.
    Puzanov, I.
    Miller, W., Jr.
    Curti, B.
    Gordon, M.
    Ernstoff, M.
    Hausman, D.
    Hunder, N.
    Thompson, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Second- or Third-Line Therapy of non-operable, locally advanced or metastatic Renal Cell Carcinoma
    Rexer, Heidrun
    Retz, Margitta
    Steiner, Thomas
    AKTUELLE UROLOGIE, 2021, 52 (05) : 425 - 426
  • [33] Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature
    ter Veer, Emil
    Mohammad, Nadia Haj
    van Valkenhoef, Gert
    Ngai, Lok Lam
    Mali, Rosa M. A.
    van Oijen, Martijn G. H.
    van Laarhoven, Hanneke W. M.
    CANCER AND METASTASIS REVIEWS, 2016, 35 (03) : 439 - 456
  • [34] Safety and continuity of second- and third-line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer
    Kimura, Michio
    Usami, Eiseki
    Kanematsu, Tetsufumi
    Iwai, Mina
    Yoshimura, Tomoaki
    Mori, Hiromi
    Sugiyama, Tadashi
    Teramachi, Hitomi
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (03) : 466 - 472
  • [35] Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature
    Emil ter Veer
    Nadia Haj Mohammad
    Gert van Valkenhoef
    Lok Lam Ngai
    Rosa M. A. Mali
    Martijn G. H. van Oijen
    Hanneke W. M. van Laarhoven
    Cancer and Metastasis Reviews, 2016, 35 : 439 - 456
  • [36] Paclitaxel plus valproic acid versus paclitaxel alone as second- or third-line therapy for advanced gastric cancer: a randomized Phase II trial
    Fushida, Sachio
    Kinoshita, Jun
    Kaji, Masahide
    Oyama, Katsunobu
    Hirono, Yasuo
    Tsukada, Tomoya
    Fujimura, Takashi
    Ohta, Tetsuo
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 2353 - 2358
  • [37] Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis
    Buchler, Tomas
    Bortlicek, Zbynek
    Poprach, Alexandr
    Kubackova, Katerina
    Kiss, Igor
    Zemanova, Milada
    Fiala, Ondrej
    Dusek, Ladislav
    Vyzula, Rostislav
    Melichar, Bohuslav
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (05) : 569 - 575
  • [38] Second- and third-line chemotherapy in patients with metastatic pancreatic adenocarcinoma: Feasibility and potential benefits in a retrospective series of 117 patients
    Bachet, J. -B.
    Mitry, E.
    Lievre, A.
    Lepere, C.
    Vaillant, J. -N.
    Declety, G.
    Parlier, H.
    Emile, J. -F.
    Julie, C.
    Rougier, P.
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2009, 33 (10-11): : 1036 - 1044
  • [39] Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines
    Berruti, A
    Sperone, P
    Bottini, A
    Gorzegno, G
    Lorusso, V
    Brunelli, A
    Botta, M
    Tampellini, M
    Donadio, M
    Mancarella, S
    De Lena, M
    Alquati, P
    Dogliotti, L
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (19) : 3370 - 3377
  • [40] Everolimus, an mTOR inhibitor, in combination with docetaxel for second- or third-line therapy of advanced-stage non-small cell lung cancer: A phase II study
    Khuri, F. R.
    Owonikoko, T. K.
    Subramanian, J.
    Sica, G.
    Behera, M.
    Saba, N. F.
    Chen, Z.
    Tighiouart, M.
    Shin, D. M.
    Sun, S.
    Fu, R.
    Gal, A.
    Govindan, R.
    Ramalingam, S. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345